Tom Powles: TIGIT and LAG3 targets have been explored
Tom Powles, Professor at the University of London, posted the following on X:
“TIGIT and LAG3 targets have been explored.
Merck has stopped their development, joining other IO disappointments(OX40,IDO, 41-BB,CD40,TIM-3 etc).
Relatlimab (LAG3) in melanoma is the exception.Its been hard to extend the initial success of PD(L)1 or CTLA4.”
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals.
His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023